Alternating drug combo plus daratumumab for newly diagnosed plasma cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia (pPCL). It uses two different drug combinations that include daratumumab, given one after the other, followed by maintenance daratumumab. The goal is to see if this approach is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been newly diagnosed with primary plasma cell leukemia (pPCL) based on specific blood and bone marrow tests.
- You have not received any previous treatment for pPCL, except for a short course of steroids (up to 4 days of dexamethasone).
- Your blood counts, liver, and kidney function are within acceptable levels (e.g., hemoglobin at least 7.0 g/dL, platelet count at least 50 or 75 x 10^9/L depending on bone marrow involvement, creatinine clearance at least 20 mL/min).
- You are able to get around and care for yourself (ECOG performance status 0 to 3), and you plan to have high-dose therapy with or without a stem cell transplant as part of your treatment.
- If you are a woman who can become pregnant, you agree to use two effective birth control methods during treatment and for 3 months after. If you are a man who can father a child, you agree to use condoms during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
This trial tests a new combination treatment for people who have just been diagnosed with primary plasma cell leukemia. The treatment includes a study drug called CM336 along with other cancer-fighting medicines. It aims to see if this combination helps control the disease.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This trial tests a new combination treatment for multiple myeloma and similar blood cancers. It aims to see if the combination works better than current options and may help people whose cancer has not responded to other treatments.
Hear when a new Primary Plasma Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.